Home > Oncology > SABCS 2021 > SABCS 2021 Focus in Genomic Profiling

SABCS 2021 Focus in Genomic Profiling

Presented By
Dr Rachel Giles, Medicom

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021


In this special-edition podcast, we focus on the clinical value of gene expression profiling tests to analyse a number of different genes in breast cancer cells to predict the risk of cancer recurrence, and to provide insight into the biological natural history of the individual tumour. The results of gene expression profiling tests can help determine who may benefit from adjuvant treatment after surgery.

Notably, this year is the 20th anniversary of the 2 seminal papers which showed that gene expression could predict clinical outcomes for breast cancer patients. That 70-gene signature, which later became Mammaprint, was published first in Nature, and then followed up a few months later with survival data in a publication in the New England Journal of Medicine.

Today we speak with the first author of the most recent New England Journal of Medicine paper, from 2016, demonstrating the clinical value of MammaPrint as a decision aid for early breast cancer, Dr Fatima Cardoso (Director Breast Unit Champalimaud Clinical Center, Lisbon, Portugal). This result from the MINDACT study was followed up in a 2021 Lancet Oncology publication, which provided level 1 evidence of the validity of that 70-gene signature. We also interview Dr William Audeh (Chief Medical Officer at Agendia BV, CA, USA) to discuss the implications of the MINDACT trial and the added value of the genomic profiling tools MammaPrint and Blueprint. Dr Audeh also touches upon the FLEX study, which provides whole transcriptome data linked with a clinical database annotated with over 800 clinical characteristics, over 90 sites in USA and > 9K patients enrolled with the ambition to enroll 30K. We also touch upon new data from the I-SPY trial, which indicates that within the high-risk region, there is also information to be gained by stratifying patients into High Risk 1 and 2 categories.

Enjoy listening!

Copyright ©2022 Medicom Medical Publisher

Posted on